Pancreatic Cancer Drug Fails Phase 2 Trial, Elicio Shares Plunge 51%
ELTX is trading near its 52-week low of $7.37 (17% below the low).
Summary
Elicio Therapeutics' Phase 2 Amplify-7P study for its pancreatic cancer treatment, ELA-002 7P, failed to meet its primary endpoint of disease-free survival. This critical setback caused shares to fall 51% in premarket trading. The news is particularly damaging given the company's recent reiteration of a 'going concern' warning and a projected cash runway only into Q4 2026. While post-hoc analysis showed some effect in a subset of patients, the overall trial failure significantly impacts the company's pipeline and ability to secure future financing. The company is now evaluating strategic financing and partnership opportunities to advance a refined Phase 3 strategy.
At the time of this announcement, ELTX was trading at $6.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $283.4M. The 52-week trading range was $7.37 to $16.00. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.